Dr. Colón brings over 25 years experience in biopharma, genomics, diagnostics, health care, drug delivery and industrial biotechnology.
In addition to her role at ProterixBio, she is President and CEO at InCarda Therapeutics, a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. She is also a senior advisor at New Science Ventures (where she was formerly a partner) and serves on the boards of Paradigm Diagnostics, PerceptiMed and Cocoon Biotech, and is an advisor at Kiverdi. She is also a member of the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University.
Previously, she was founding President of the Industrial Products Division and Senior Vice President at Intrexon Corporation (NYSE:XON) where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals and was a key contributor to the company’s $100M Series E raise.
Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences (Nasdaq:GILD), where she was responsible for global execution of clinical trials. At Gilead, she also created and led both the Alliance Management and Commercial Strategic Planning groups.
Prior to Gilead, she was VP, Corporate Planning at Affymetrix (acquired by ThermoFisher), where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics.
Earlier in her career, Grace was a consultant at McKinsey & Company, where she served clients in healthcare, high tech, consumer goods and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.
Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow and recipient of multiple NIH training grants. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
Dr. Miller has over 20 years of experience developing and launching products in the life science and high technology industries. He previously held the position of Chief Operating Officer at ProterixBio and was General Manager of the Boston site.
Prior to ProterixBio, he held the position of VP of Product Development and Operations as BioScale. He had joined BioScale soon after its founding and led product development for the company’s first product, an automated immunoassay platform utilizing a unique non-optical detection method based on MEMS technology. As VP of Product Development, he managed a multi-disciplinary team of scientists and engineers covering instrumentation, software, consumables and assay development. He led the transition of the product into manufacturing and subsequently took on additional operations responsibilities, including field support, manufacturing and facilities.
Prior to BioScale, Dr. Miller held several product development leadership positions at Axsun Technologies, a company producing optical subsystems for telecommunications and medical device markets. His responsibilities spanned the phases of early prototype development, system qualification, and manufacturing scale-up.
Prior to Axsun, he was a Principal Engineer at Physical Sciences Inc., where he worked on instrumentation and control devices for aerospace applications. While at PSI, he initiated a new business area focused on MEMS technology, winning multiple research grants to support the development of multiple novel devices.
Dr. Miller earned a B.S. in Mechanical Engineering from the Rensselaer Polytechnic Institute, and an M.S. and Ph.D. in Mechanical Engineering from Stanford University. He is inventor or co-inventor on over 25 issued patents with an additional 20 pending patent applications.
Edward Crawley is the Ford Professor of Engineering at MIT, where he has been on the faculty since 1980. From 2011 to 2016 he served simultaneously as the founding President and CEO of the Skolkovo Institute of Science and Technology in Moscow Russia, a new science-based university dedicated to driving innovation in the Russian economy. In the US he has participated in the founding of four technology-based entrepreneurial companies (ACX, Bisoscale, DataXu and Ekotrope), and for nine years was a member of the board of the Orbital Science Corporation (now merged into Orbital ATK).
At MIT, his research has focused recently on the domain of the architecture, design and decision support in complex technical systems, summarized in his recent book – System Architecture: the strategy and design of complex products (Pearson 2015).
Dr. Crawley is a member of four national academies of engineering: the Royal Swedish Academy of Engineering Science, the (UK) Royal Academy of Engineering, the Chinese Academy of Engineering and the US National Academy of Engineering.
Igor Goryanin is a Professor and the Henrik Kacser Chair in Computational Systems Biology at the University of Edinburgh since 2005. He co-founded the Centre for Systems Biology at Edinburgh, where he was a co-director from 2006–2010, and the Edinburgh Centre for Bioinformatics, where he was a director from 2005–2010. He also is an adjunct Professor at Tianjin Institute of Industrial Biotechnology at the Chinese Academy of Sciences and also heads the Biological Systems Unit at the Okinawa Institute of Science and Technology, Japan. He is also cofounder of the Institute of Systems Biology in Russia. From 2010-2012 he held the position as Executive Director of the cluster of biological and medical technology of the Skolkovo Foundation in Russia.
Dr. Goryanin held a number of senior management positions at GlaxoSmithKline (King of Prussia, PA) from 1997 to 2005 where he directed initiatives in comparative biology and developed computational methods to model cells and organisms to aid in the discovery of drugs and to improve manufacturing processes. Prior to that he worked as a Visiting Computer Scientist at the Mathematics & Computer Science Division, at the Argonne National Laboratories, USA.
Dr. Goryanin graduated from the Moscow Engineering Physics Institute in applied mathematics obtained his PhD in biophysics, focusing on the development of a software for mathematical stimulation and analysis of the cellular metabolism and regulation.
He is the co-founder and CEO of Biobank Inc., a principal investigator of the systems biology project “Pathway Editor”, co-founder of the first systems biology alliance IECA (International E. coli alliance) and “Systems Biology Graphical Notation”. He authored DBsolve, a software tool for mathematical simulation and analysis of cellular metabolism and regulation.
In addition to his academic and industry appointments, Dr. Goryanin has been a venture investor and was a Managing Partner with Polar Star Ventures from 2012-2014.
Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures (NSV). He serves on the Board of Directors of Achronix Semiconductor Corporation, Akarna Therapeutics, Ralexar Therapeutics, Cambridge Epigenetix, Dali Wireless, Oxyrane, Resolve Therapeutics, Svelte Medical Systems, TigerText, Vaultive, Vascular Therapies, and iCAD. Somu has also served on the Boards of Dezima Pharma (acquired by Amgen), Ception (acquired by Cephalon), BioVex (acquired by Amgen), and Lightwire (acquired by Cisco). Prior to founding NSV, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.
Mark is a serial cross-industry entrepreneur, having co-founded companies in material science, satellite communications, software, and bioscience. In 2002, Mark founded BioScale, which has developed some of the world’s most sensitive scales for nanotechnology measurement of proteins, cells, viral load, hormones, bacteria, and small molecules for research and diagnostic applications. Prior to BioScale, Mark co-founded Active Control eXperts, Inc. (ACX), which designed and manufactured piezoelectric systems used to control vibrations. ACX was acquired by Cymer, but their products are still found in a wide variety of equipment such as skis, baseball bats, and machine tools. In the software industry, Mark founded Ripcord Systems which created wireless products to arm on-the-road employees with anytime, anywhere access to critical information from corporate enterprise systems. He was also on the start-up team at Teledesic LLC, building the world’s first global, broadband Internet-in-the-SkyTM network using advanced satellite technology, and was in engineering and management at NASA (JPL) and Boeing. Mark served on the Board of Directors of the Massachusetts Institute of Technology and serves as Chairman and Founder of SkiAble, a charity dedicated to providing skiing and other athletic opportunities to disabled children. Mark has been a “Young Leader” on the National Committee for US-China Relations and is a Life Member of the Council on Foreign Relations. In his earlier years, Mark spent several years as a competitive ski racer, he holds a pilot’s license, and has 16 patents in diverse industries. Mark earned his M.Phil. in Economics from Oxford University where he was a Rhodes Scholar, and an MBA from MIT’s Sloan School of Management as a Leaders for Manufacturing Fellow. He earned both a BS and MS in Aeronautics and Astronautics from MIT. He is a 2013 Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.